Loading the company…
Loading the company…
In 2025, Neuropace reported engagement with 444 surgeons and other clinicians in the states MedaRep covers, worth $382K in consulting, speaking, meals and travel for its device products, the most in New York ($86K to 32). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($86K, 32 engaged), Michigan ($58K, 13 engaged), California ($47K, 88 engaged), Colorado ($41K, 23 engaged), Massachusetts ($34K, 9 engaged).
In the last ten years FDA made 53 decisions for Neuropace (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2019 (12). The latest was on 2026-08-19.
| Family | Decisions on record |
|---|---|
| DBS & VNS | 99 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-08-19 | PMA | P100026-S104 | NeuroPace® RNS® System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-06-17 | PMA | P100026-S100 | NeuroPace® RNS® System · Change Design/Components/Specifications/Material |
| 2026-05-28 | PMA | P100026-S101 | NeuroPace® RNS® System · Change Design/Components/Specifications/Material |
| 2026-02-20 | PMA | P100026-S103 | NeuroPace® RNS® System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-08-18 | PMA | P100026-S099 | NeuroPace® RNS® System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Neuropace.